doripenem has been researched along with Obesity in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheatham, SC; Chung, EK; Fleming, MR; Juenke, JM; Kays, MB | 1 |
| Cheatham, SC; Chung, EK; Fleming, MR; Kays, MB | 1 |
| Lipman, J; Roberts, JA | 1 |
| van der Meer, YG; van Zanten, AR | 1 |
2 trial(s) available for doripenem and Obesity
| Article | Year |
|---|---|
Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Doripenem; Female; Gram-Negative Bacteria; Humans; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Obesity; Thienamycins | 2014 |
Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility.
Topics: Anti-Bacterial Agents; Carbapenems; Creatinine; Critical Illness; Cross Infection; Doripenem; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Intensive Care Units; Male; Middle Aged; Monte Carlo Method; Obesity; Pneumonia, Bacterial | 2013 |
2 other study(ies) available for doripenem and Obesity
| Article | Year |
|---|---|
Population Pharmacokinetics and Pharmacodynamics of Doripenem in Obese, Hospitalized Patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Body Mass Index; Body Weight; Carbapenems; Doripenem; Female; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Monte Carlo Method; Obesity | 2017 |
Prolonged infusion of carbapenems in critically ill patients: time to extend our practice.
Topics: Anti-Bacterial Agents; Carbapenems; Creatinine; Doripenem; Female; Humans; Male; Obesity; Pneumonia, Bacterial | 2013 |